Home >  Pulmonology MDTV >  Pulmonology Shorts >  Atypical type of...

Atypical type of Macrophages Enable Alveolar Regeneration Following Lung Injury: Study

By - Dr. Nandita Mohan
Published On 2024-08-05 03:00 GMT   |   Update On 2024-08-05 08:45 GMT
Advertisement
The lung is constantly exposed to airborne pathogens and particles that can cause alveolar damage. Hence, appropriate repair responses are essential for gas exchange and life.
Here, the authors deciphered the spatiotemporal trajectory and function of an atypical population of macrophages after lung injury. Post–influenza A virus (IAV) infection, short-lived monocyte-derived Ly6G-expressing macrophages were recruited to the alveoli of lung perilesional areas.
Advertisement
Ly6G+ Macs engulfed immune cells, exhibited a high metabolic potential, and clustered with alveolar type 2 epithelial cells (AT2s) in zones of active epithelial regeneration. Ly6G+ Macs were partially dependent on granulocyte-macrophage colony-stimulating factor and interleukin-4 receptor signaling and were essential for AT2-dependent alveolar regeneration.
Similar macrophages were recruited in other models of injury and in the airspaces of lungs from patients with suspected pneumonia. This study identifies perilesional alveolar Ly6G+ Macs as a spatially restricted, short-lived macrophage subset promoting epithelial regeneration postinjury, thus representing an attractive therapeutic target for treating lung damage.
Ref: Cecilia Ruscitti et al. ,Recruited atypical Ly6G+ macrophages license alveolar regeneration after lung injury.Sci. Immunol.9,eado1227(2024).DOI:10.1126/sciimmunol.ado1227 
Full View
Tags:    
Article Source : Science Immunology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Managing Nasal Congestion in Allergic Rhinitis: Whats the Mechanism of Action of Allegra D ?

WHO Leads Global Call to Include Pregnant, Lactating Women in TB Research

COVID-19 Linked to Higher Risk of Asthma and Sinusitis: Study Finds

PCV20 Launch in India: A Single Dose, Science-Driven Approach for Pneumococcal Disease Control

Study Reveals Social Factors that May Triple the Risk of Long Covid

Maternal RSV Vaccine Cuts Infant Hospitalizations by 72 Percent: Study Finds

Micro labs to offer mucolytic solution for respiratory care with its recently launched Pulmucus range

Why Asthma Often Comes Back After Stopping Biologic Drugs? Study Sheds Light